| Dr Pamela Joyce Gray, MD | |
|
403 S Early Station Rd, Ahoskie, NC 27910-9671 | |
| (757) 613-3233 | |
| Not Available |
| Full Name | Dr Pamela Joyce Gray |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Rheumatology |
| Location | 403 S Early Station Rd, Ahoskie, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548254030 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 0101031088 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Pamela Joyce Gray, MD 403 S Early Station Rd, Ahoskie, NC 27910-9671 Ph: (757) 613-3233 | Dr Pamela Joyce Gray, MD 403 S Early Station Rd, Ahoskie, NC 27910-9671 Ph: (757) 613-3233 |
News Archive
With the election over, the health care and other industries are taking stock of the health law's effects.
Writing in the January 3 issue of Cancer Cell, researchers at University of California San Diego School of Medicine report that detection of "copy editing" by a stem cell enzyme called ADAR1, which is active in more than 20 tumor types, may provide a kind of molecular radar for early detection of malignancies and represent a new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.
An experimental HIV vaccine raises hope of reducing the risk of infection. Wall Street Journal/Associated Press reports: "For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible."
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
› Verified 3 days ago
Dr. Daniel Gottovi, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 120 Health Center Dr, Ahoskie, NC 27910 Phone: 252-332-3548 Fax: 252-332-1665 | |
Dr. Jason Joseph Thomas, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 500 Academy St S, Ahoskie, NC 27910 Phone: 252-209-3708 Fax: 252-209-3709 | |
Dr. Shafqat Hamza Ashai, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 500 Academy St S, Ahoskie, NC 27910 Phone: 252-209-3148 Fax: 252-209-3146 | |
Dr. Apoorva Vivek Saoji, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 500 S Academy St, Hospitalist Department, Attn Lou Harrell, Ahoskie, NC 27910 Phone: 252-209-3000 Fax: 313-966-1738 | |
Pierre S Selwane, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 500 Academy St S, Ahoskie, NC 27910 Phone: 551-497-3735 | |
Mr. Gilberto Pabalan Navarro, MD Rheumatology Medicare: May Accept Medicare Assignments Practice Location: 120 Health Center Dr, Ahoskie, NC 27910 Phone: 252-209-0237 Fax: 252-209-0197 | |
Dr. Renuka Ananth Kalyan Kadali, M.D., M.S Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 500 Academy St S, Suite B-8, Ahoskie, NC 27910 Phone: 252-209-3708 |